Difference between revisions of "Fibrinogen alpha chain (TG2)"
m |
m |
||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
− | |||
− | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 58: | Line 56: | ||
| | | | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] |
Latest revision as of 11:37, 10 March 2015
Fibrinogen alpha chain (TG2) | |
---|---|
Substrate peptide name | Fibrinogen alpha chain |
Synonyms | - |
Determination type | In vitro |
Source | Homo sapiens |
Subcellular localization | Extracellular; plasma |
Swissprot ID | P02671 |
Reactive glutamines | Q328, Q366 |
Reactive lysines | K148, K230, K303, K413 |
Substrate sequence | GSTGNQNPGSP
SGSTGQWHSES QLVDMKRELVD VPPEWKALTDM GTATWKPGSSG EYHTEKLVTSK |
Structure | 1LT9 |
Surface accessibility | |
Disorder prediction | IUPred |
Reference | PMID:10816585 |
Notes | |